Phase II study of allovectin-7 as an immunotherapeutic agent in patients with stages III and IV melanoma
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2011
At a glance
- Drugs Velimogene aliplasmid (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Jun 2011 Results presented at 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011).
- 11 Jan 2011 Results from this trial have been published in the journal Immunotherapy, according to a Vical media release.
- 12 May 2010 Results have been published in Melanoma Research, and Expert Opinion on Biological Therapy, according to a Vical media release.